Ask Dr. Nandi: FDA wants two months of safety data before considering COVID-19 vaccine

There are new FDA guidelines for coronavirus vaccine developers. Two months of follow-up data on volunteers in phase 3 trials are now needed before Emergency Use Authorization will be considered.